18F-氟他硝唑乏氧PET在二甲双胍联合放疗的肺癌异种移植模型中作为预后和预测影像生物标志物具有前景
研究在A549非小细胞肺癌异种移植小鼠中,用18F-氟他硝唑PET评估二甲双胍急性给药后肿瘤乏氧变化,并验证单次二甲双胍联合放疗对长期疗效的影响。结果显示二甲双胍后30分钟肿瘤/本底比值(TBR)从3.21±0.13降至2.87±0.13(P=0.0001),三组中位肿瘤倍增时间分别为19、34、52天(log-rank P<0.0001),基线TBR及TBR变化均为肿瘤倍增时间的预后生物标志物。
要点
- 二甲双胍后30分钟,18F-氟他硝唑TBR均值从3.21±0.13降至2.87±0.13(P=0.0001)。
- 对照组、放疗组、二甲双胍+放疗组中位肿瘤倍增时间分别为19、34、52天(log-rank P<0.0001)。
- 基线TBR(HR 2.0,P=0.0004)和TBR变化(HR 0.39,P=0.04)均为肿瘤倍增时间的预后生物标志物。
核心结论
- 在非小细胞肺癌异种移植模型中,18F-氟他硝唑PET显示二甲双胍可能通过增加肿瘤氧合发挥放疗增敏作用,基线18F-氟他硝唑有潜力作为影像生物标志物。
研究设计与样本
- 研究为A549肿瘤荷瘤小鼠实验:先进行基线18F-氟他硝唑PET/CT扫描,次日静脉注射100 mg/kg二甲双胍,30分钟后再次PET/CT评估肿瘤乏氧变化。
- 两天后将小鼠分为3组:对照组(组1)、放疗组(组2)、二甲双胍+放疗组(组3),分别静脉给予生理盐水(组1-2)或二甲双胍100 mg/kg(组3),30分钟后给予单次10 Gy放疗(组2-3)或假照射(组1)。
- 肿瘤生长通过卡尺测量每周监测三次,计算相对基线肿瘤体积,以肿瘤倍增时间(TDT,即达到照射前肿瘤体积两倍的时间)为终点。
主要发现
- 二甲双胍治疗后30分钟,18F-氟他硝唑PET显示肿瘤乏氧显著变化,平均瘤内TBR从3.21±0.13降至2.87±0.13(P=0.0001)。
- 总体相对肿瘤体积随时间变化在各治疗组间存在差异(P<0.0001)。
- 对照组、放疗组、二甲双胍+放疗组的中位TDT分别为19、34、52天(log-rank P<0.0001)。
- 基线18F-氟他硝唑TBR(风险比2.0;P=0.0004)和从基线的TBR变化(风险比0.39;P=0.04)均为TDT的预后生物标志物,与治疗无关。
- 基线TBR可预测二甲双胍特异性治疗效果,该效果依赖于基线肿瘤乏氧。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metformin may improve tumor oxygenation and thus radiotherapy response, but imaging biomarkers for selection of suitable patients are still under investigation. First, we assessed the effect of acute metformin administration on non-small cell lung cancer xenograft tumor hypoxia using PET imaging with the hypoxia tracer 18F-flortanidazole. Second, we verified the effect of a single dose of metformin before radiotherapy on long-term treatment outcome. Third, we examined the potential of baseline 18F-flortanidazole as a prognostic or predictive biomarker for treatment response. Methods: A549 tumor-bearing mice underwent a 18F-flortanidazole PET/CT scan to determine baseline tumor hypoxia. The next day, mice received a 100 mg/kg intravenous injection of metformin. 18F-flortanidazole was administered intravenously 30 min later, and a second PET/CT scan was performed to assess changes in tumor hypoxia. Two days later, the mice were divided into 3 therapy groups: controls (group 1), radiotherapy (group 2), and metformin + radiotherapy (group 3). Animals received saline (groups 1-2) or metformin (100 mg/kg; group 3) intravenously, followed by a single radiotherapy dose of 10 Gy (groups 2-3) or sham irradiation (group 1) 30 min later. Tumor growth was monitored triweekly by caliper measurement, and tumor volume relative to baseline was calculated. The tumor doubling time (TDT), that is, the time to reach twice the preirradiation tumor volume, was defined as the endpoint. Results: Thirty minutes after metformin treatment, 18F-flortanidazole demonstrated a significant change in tumor hypoxia, with a mean intratumoral reduction in 18F-flortanidazole tumor-to-background ratio (TBR) from 3.21 ± 0.13 to 2.87 ± 0.13 (P = 0.0001). Overall, relative tumor volume over time differed across treatment groups (P < 0.0001). Similarly, the median TDT was 19, 34, and 52 d in controls, the radiotherapy group, and the metformin + radiotherapy group, respectively (log-rank P < 0.0001). Both baseline 18F-flortanidazole TBR (hazard ratio, 2.0; P = 0.0004) and change from baseline TBR (hazard ratio, 0.39; P = 0.04) were prognostic biomarkers for TDT irrespective of treatment, and baseline TBR predicted metformin-specific treatment effects that were dependent on baseline tumor hypoxia. Conclusion: Using 18F-flortanidazole PET imaging in a non-small cell lung cancer xenograft model, we showed that metformin may act as a radiosensitizer by increasing tumor oxygenation and that baseline 18F-flortanidazole shows promise as an imaging biomarker.
引用
- De Bruycker S, Vangestel C, Van den Wyngaert T, et al. 18F-Flortanidazole Hypoxia PET Holds Promise as a Prognostic and Predictive Imaging Biomarker in a Lung Cancer Xenograft Model Treated with Metformin and Radiotherapy. J Nucl Med. 2018. PMID: 29980581. doi:10.2967/jnumed.118.212225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。